Latest period
$1.91B
YoY change
-11.5%
5Y CAGR
+35.7%
Peak year (2024)
$2.29B
Latest annual
$2.03B
Cash on Hand history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: $2.03B
Cash on Hand growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: -11.5%
Cash on Hand history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | $2.03B | -11.5% | −$263.62M | ||
| 2024 | $2.29B | +23.5% | +$436.34M | ||
| 2023 | $1.85B | +187.3% | +$1.21B | ||
| 2022 | $644.94M | +11.8% | +$67.89M | ||
| 2021 | $577.05M | +30.9% | +$136.31M | ||
| 2020 | $440.74M | +259.0% | +$317.98M | ||
| 2019 | $122.76M | +76.4% | +$53.17M | ||
| 2018 | $69.59M | +666.5% | +$60.51M | ||
| 2017 | $9.08M | — | — |
- 2025$2.03B-11.5%
- 2024$2.29B+23.5%
- 2023$1.85B+187.3%
- 2022$644.94M+11.8%
- 2021$577.05M+30.9%
- 2020$440.74M+259.0%
- 2019$122.76M+76.4%
- 2018$69.59M+666.5%
- 2017$9.08M—
Cash on Hand values are taken from Revolution Medicines's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Revolution Medicines (RVMD)
According to Revolution Medicines's latest reported financial statements, the company's latest reported cash and short-term investments is $1.91B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual cash and short-term investments for Revolution Medicines (RVMD) came in at $2.03B – declined 11.5% year-over-year.
Through 2020–2025 (5 years), Revolution Medicines cash and short-term investments delivered a +35.7% annualised rate; with mixed annual results across the window.
Revolution Medicines cash and short-term investments declined from $2.29B in 2024 to $2.03B in 2025, a 11.5% drawdown.
Across the available history, cash and short-term investments reached its high of $2.29B in 2024 and its low of $9.08M in 2017.
Revolution Medicines Cash on Hand by Year
Revolution Medicines Cash on Hand 2025: $2.03B
Revolution Medicines posted cash and short-term investments of $2.03B in 2025, declined 11.5% below 2024.
Revolution Medicines Cash on Hand 2024: $2.29B
In 2024, Revolution Medicines reported cash and short-term investments of $2.29B, grew 23.5% from 2023. This figure represents the highest annual value in the available history.
Revolution Medicines Cash on Hand 2023: $1.85B
Revolution Medicines cash and short-term investments in 2023 was $1.85B, surged 187.3% from 2022.
Revolution Medicines Cash on Hand 2022: $644.94M
2022's cash and short-term investments for Revolution Medicines came in at $644.94M, grew 11.8% from 2021.
Revolution Medicines Cash on Hand 2021: $577.05M
Revolution Medicines cash and short-term investments in 2021 was $577.05M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by Cash on Hand
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation